Purpose/Objective: The aim of this study is to validate a frameless approach for the integration of two-dimensional (2D) digital subtracted angiography (DSA) images with threedimensional (3D) computed tomography angiography (CTA) and magnetic resonance angiography (MRA) datasets using vessel tree segmentation for image registration for arteriovenous malformation (AVM) radiosurgery. Materials and Methods: A retrospective analysis of 28 AVM patients with DSA, CTA and MRA imaging was performed. Vessel tree segmentation of CTA/MRA was used to register these 3D-image sets with 2D DSA. AVM contouring on DSA is projected on the CTA/MRA and used as a guide to segment and delineate the lesion on CTA and MRA. Based on these contours, the localization accuracy was evaluated comparing the new vessel tree-based image registration (frameless approach) with external coordinates localization (framebased approach). Results: In all 28 cases, a vessel tree could be mapped out of CTA and MRA datasets and used to register with DSA. DSA contouring resulting in a 3D AVM contour on CTA showed a mean volume of 1.60 cc for both approaches. The targeting accuracy of the new application with vessel tree segmentation was found 0.4 ± 0.3 mm, 0.5 ± 0.3 mm and 0.3 ± 0.3 mm for the CC, LAT and AP direction, respectively, resulting in an overall 3D vector of 0.8 ± 0.4 mm. The agreement ratio, which reflects the similarity between the two approaches, was 0.75 ± 0.12. Conclusions: Registration of 2D DSA images with 3D CTA/MRA based on vessel tree segmentation is a feasible option for frameless AVM targeting and showed submillimetric targeting accuracy. Purpose/Objective: MLC tracking is a promising method for intrafraction tumor motion management by real-time adaption of the MLC aperture to the moving target. However, limitations in MLC adaptation leads to residual dosimetric errors. Here, we present an MLC tracking simulator and demonstrate its use for large-scale simulations to quantify the dosimetric benefit of potential tracking system design improvements Materials and Methods: A Varian TrueBeam accelerator with MLC tracking guided by the Calypso electromagnetic transponder system was used as reference for the simulator. The Calypso system delivers a 3D position of the target every 40ms to the tracking system. Similar to the accelerator, the tracking simulator performs three steps every 10ms. 1) Estimate the target position, 2) fit the MLC shape to the estimated target position, and 3) adjust the MLC leaves to the fitted MLC shape. For each of these three steps, the residual adaptation error was quantified by the underexposed area Au (MLC shielded area that should ideally be exposed) and the over-exposed area Ao (MLC exposed area that should ideally be shielded). It has previously been shown that Au+Ao is a good surrogate for the dosimetric error. Tracking log files from the accelerator were analyzed and used to build the MLC dynamics into the simulator. The MLC tracking simulator was used to test the following potential improvements of the tracking system: A) Halving the latency (improves target localization), B) Halving the MLC leaf width from 5 mm to 2.5 mm (improves MLC fitting), C) Dynamic alignment of the collimator during arc treatments such that the leaves move along a preferred target motion direction (improves MLC fitting). For all potential improvements, the reduction in Au+Ao was calculated and used to test whether the improvement was statistically significant. The base system and each simulated improved system were tested with two high-modulated VMAT plans (lung and prostate) for 100 patient-measured tumor traces from motion databases (50 lung and 50 prostate). Only traces with motion larger than 5 mm were chosen for the simulations. Results: For lung, the mean Au+Ao was on average reduced by 5.4 % (Half latency, p= 0.00), 23.5 % (Half leaf width, p= 0.00) and 10.8 % (Dynamic collimator rotation, p= 0.04) by the tested tracking system improvements. For prostate, Au+Ao was reduced by 6.36 % (Half latency, p= 0.00), 21.1% (Half leaf with, p= 0.00) and 8 % (Dynamic collimator rotation, p= 0.10). The figure illustrates that for both tumor sites, the primary source of residual errors is leaf fitting, followed by leaf adjustment errors for lung tumor motion and by errors caused by the latency for prostate motion.
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Conclusions:
A framework for MLC tracking simulations was built. All system modification simulated gave a reduction of the residual error, however it was not statistical significant for prostate and collimator rotation. For both prostate and lung tumor motion, halved leaf width resulted in the largest tracking performance improvement. 
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Conclusions:
The magnitudes of the dose mapping uncertainties caused by the registration uncertainty emphasize the need of estimating these values prior to any clinical application of dose mapping. The proposed procedure gives a conservative estimate of the uncertainty by assuming the same registration uncertainty for all voxels, and by collecting all doses within the uncertainty volume. Extending this procedure to include voxel-wise registration uncertainty and its shape is part of future research. Each plan was delivered twice on the Quasar phantom, the first without movement and the second with motion of 1 cm peak to peak at 12 breaths per minute (BPM). A relative comparison between the dose distributions measured and those calculated on the TPS was performed and the PUMA method used to analyse the effect of motion on the plans. The results were also compared to those obtained on the Quasar phantom. The criteria for evaluation was set to be < 5% of points with gamma 3%,3 mm > 1% on the comparison between static and dynamic dose distributions recorded on radiochromic films and < 5% of points with > 3% difference dose between PUMA and the TPS. These were compared to the results obtained on the Quasar phantom. Results: Figure 1 shows the comparison between both methods where, except for plan 7, they agree on the pass criteria. In this case PUMA, which analyses all target volumes, fails while the radiochromic film passes. This suggests that PUMA, which analyses the volumetric dose distribution, is more sensitive to interplay effect analysis than the analysis performed on one plane by using Quasar.
